Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CALCRL | Q16602 | 12/20 | 0.48 |
| ▸ | RAMP1 | O60894 | 5/20 | 0.48 |
| ▸ | ADM2 | Q7Z4H4 | 5/20 | 0.48 |
| ▸ | CALCB | P10092 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24220794 | 1.00 | CALCA (0.50) | CALCANPC1ALDH1A1CYP1A2GAA | |
| SCHEMBL12634313 | 0.90 | CALCA (0.54) | CALCACALCRLADM2CALCB | |
| SCHEMBL27308573 | 0.89 | CALCA (0.52) | CALCACALCRLRAMP1ADM2CALCB | |
| SCHEMBL10246001 | 0.86 | CALCRL (0.51) | CALCACALCRLRAMP1ADM2CALCB | |
| SCHEMBL22110811 | 0.85 | CALCRL (0.51) | CALCRLRAMP1 | |
| SCHEMBL15935914 | 0.85 | ALDH1A1 (0.42) | CALCANPC1ALDH1A1CYP1A2GAA | |
| SCHEMBL24962033 | 0.84 | CALCA (0.48) | CALCACALCRLRAMP1ADM2CALCB | |
| SCHEMBL2056346 | 0.84 | CALCA (0.48) | CALCACALCRLRAMP1ADM2CALCB | |
| SCHEMBL260524 | 0.84 | CALCA (0.50) | CALCACALCRLRAMP1ADM2CALCB | |
| SCHEMBL550614 | 0.84 | CALCA (0.50) | CALCACALCRLRAMP1ADM2CALCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-01-27 | — | — | US | disclosed |
| WO-2020099882-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
| US-8952014-B2 | Pyrimidine derivatives which are CGRP—antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952014-B2 | Pyrimidine derivatives which are CGRP—antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130245009-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-8450327-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-20120149698-A1 | NOUVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120088755-A1 | Novel Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-20110306626-A1 | IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | Merck, Sharp & Dohme Corp. | 2011-12-15 | — | — | US | disclosed |
| US-20110172218-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | US | disclosed |
| US-7947678-B2 | Heterocyclic benzodiazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20090105228-A1 | Heterocyclic benzodiazepine cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088755-A1 | Novel Compounds | SLC26A4, F12, SLCO1B3 | CALCA 440/4885NPC1 1283/4885ALDH1A1 887/4885 |
| US-20110021500-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | CALCA 3/4885NPC1 1476/4885ALDH1A1 1445/4885 |
| US-20090105228-A1 | Heterocyclic benzodiazepine cgrp receptor antagonists | BDKRB2, BDKRB1, CCKBR | CALCA 107/4885NPC1 954/4885ALDH1A1 2910/4885 |
| US-20110306626-A1 | IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | CALCRL, BDKRB2, CALCR | CALCA 15/4885NPC1 537/4885ALDH1A1 2432/4885 |
| US-20120149698-A1 | NOUVEL COMPOUNDS | BDKRB2, CALCR, CALCRL | CALCA 22/4885NPC1 1342/4885ALDH1A1 1217/4885 |
| US-20130245009-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, BDKRB2 | CALCA 7/4885NPC1 1406/4885ALDH1A1 856/4885 |
| US-20110172218-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | CALCA 3/4885NPC1 1482/4885ALDH1A1 1371/4885 |
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, AGTR1 | CALCA 244/4885NPC1 1561/4885ALDH1A1 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.